Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
5.160 CHF
15.55 B CHF
58.10 B CHF
2.50 B
About Merck & Company, Inc.
Sector
Industry
CEO
Robert M. Davis
Website
Headquarters
Rahway
Founded
1891
ISIN
US58933Y1055
FIGI
BBG006TLRZM7
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Related stocks
MERCK BULLISH (in long time)
. Overall Setup
The stock has been in a prolonged downtrend (red descending channel), which was broken by a falling wedge pattern (a bullish reversal signal).
After the breakout, price attempted to recover but was rejected around Top 1 – Top 2 (~$86).
It is now pulling back toward a key support zo
More Downside in Merck?Merck has been sliding for more than a year. Now, following a period of consolidation, some traders may see further downside risk.
The first pattern on today’s chart is the range between the August 26 high of $85.59 and the August 28 close of $83.21, where the pharmaceutical giant spent almost thre
MRkStock: Merck & Company (MRK) – NYSE
Timeframe: 1H (short–to–mid term outlook)
Current Situation
The stock is trading around 85.16 – 85.33.
It has broken out of a long descending channel (yellow zone), signaling a potential trend reversal to the upside.
Suggested entry on the chart: Buy at 84.80
MRK is showing some breakout signsThe white fork is pointing slightly to the upside.
CIB is broken and signals a change in behavior. The pullback to it was very nice - a Eye twinkle? §8-)
Then price opened the door to the upside by peeking through the resistance of the consolidation, asking: "Anybody here to buy me?"...silence...
double top includes a solid major high as second top=SELL1->3 : we create a double top with the area above 1 and 3 being a
pressure zone pushing price down
2: this is the low created when sellers entered the first time
4: the is the low created when sellers entered the second time
3 : due to the fact that the sellers that originated from 3 created
Is Merck Ready for a Rebound?Fundamental Analysis
Financial Performance
Revenue Decline: Q2 revenue fell 2% year-over-year to $15.8 billion.
Earnings Drop: Adjusted earnings per share decreased by 7% to $2.13.
Key Product Challenges
Keytruda Competition: Facing increased competition for its top cancer drug, Keyt
MRK eyes on $80.36/74: Double Golden zone could mark the bottomPharma has been struggling with Trump's tariff threats.
This one is orbiting a Double Golden zone at $80.36-80.74
Looking for a clean Break-n-Retest for possible long entries.
Can Global Chaos Fuel Pharmaceutical Giants?Merck's remarkable growth trajectory demonstrates how a pharmaceutical leader can transform global uncertainties into strategic advantages. The company has masterfully navigated geopolitical tensions, including US-China trade disputes, by diversifying supply chains and establishing regionalized manu
MRK potentially enters the Wyckoff accumulation phase this week.The weekly chart points strongly towards a stock emerging from a prolonged Markdown Phase and potentially entering Accumulation (Phase C), with signs of strength appearing.
Merck is basically yelling 'buy me' across all timeframes, so I'm jumping into a long call
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
MRK5584756
Merck & Co., Inc. 5.15% 17-MAY-2063Yield to maturity
5.46%
Maturity date
May 17, 2063
MRK6166087
Merck & Co., Inc. 5.7% 15-SEP-2055Yield to maturity
5.42%
Maturity date
Sep 15, 2055
MRK5584755
Merck & Co., Inc. 5.0% 17-MAY-2053Yield to maturity
5.39%
Maturity date
May 17, 2053
US58933YBF1
Merck & Co., Inc. 2.75% 10-DEC-2051Yield to maturity
5.38%
Maturity date
Dec 10, 2051
MRK5319197
Merck & Co., Inc. 2.9% 10-DEC-2061Yield to maturity
5.37%
Maturity date
Dec 10, 2061
MRK4806294
Merck & Co., Inc. 4.0% 07-MAR-2049Yield to maturity
5.35%
Maturity date
Mar 7, 2049
MRK5002693
Merck & Co., Inc. 2.45% 24-JUN-2050Yield to maturity
5.33%
Maturity date
Jun 24, 2050
US58933YAT2
Merck & Co., Inc. 3.7% 10-FEB-2045Yield to maturity
5.31%
Maturity date
Feb 10, 2045
MRK5584925
Merck & Co., Inc. 4.9% 17-MAY-2044Yield to maturity
5.28%
Maturity date
May 17, 2044
US58933YAJ4
Merck & Co., Inc. 4.15% 18-MAY-2043Yield to maturity
5.26%
Maturity date
May 18, 2043
MRK3900816
Merck & Co., Inc. 3.6% 15-SEP-2042Yield to maturity
5.23%
Maturity date
Sep 15, 2042
See all 6MK bonds
Curated watchlists where 6MK is featured.
Frequently Asked Questions
The current price of 6MK is 71.887 CHF — it has increased by 0.63% in the past 24 hours. Watch Merck & Co., Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Merck & Co., Inc. stocks are traded under the ticker 6MK.
6MK stock has risen by 15.22% compared to the previous week, the month change is a 4.48% rise, over the last year Merck & Co., Inc. has showed a −25.26% decrease.
We've gathered analysts' opinions on Merck & Co., Inc. future price: according to them, 6MK price has a max estimate of 111.65 CHF and a min estimate of 64.93 CHF. Watch 6MK chart and read a more detailed Merck & Co., Inc. stock forecast: see what analysts think of Merck & Co., Inc. and suggest that you do with its stocks.
6MK stock is 0.84% volatile and has beta coefficient of 0.48. Track Merck & Co., Inc. stock price on the chart and check out the list of the most volatile stocks — is Merck & Co., Inc. there?
Today Merck & Co., Inc. has the market capitalization of 177.74 B, it has increased by 5.51% over the last week.
Yes, you can track Merck & Co., Inc. financials in yearly and quarterly reports right on TradingView.
Merck & Co., Inc. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
6MK earnings for the last quarter are 1.69 CHF per share, whereas the estimation was 1.61 CHF resulting in a 4.77% surprise. The estimated earnings for the next quarter are 1.88 CHF per share. See more details about Merck & Co., Inc. earnings.
Merck & Co., Inc. revenue for the last quarter amounts to 12.54 B CHF, despite the estimated figure of 12.59 B CHF. In the next quarter, revenue is expected to reach 13.56 B CHF.
6MK net income for the last quarter is 3.51 B CHF, while the quarter before that showed 4.50 B CHF of net income which accounts for −21.88% change. Track more Merck & Co., Inc. financial stats to get the full picture.
Yes, 6MK dividends are paid quarterly. The last dividend per share was 0.64 CHF. As of today, Dividend Yield (TTM)% is 3.63%. Tracking Merck & Co., Inc. dividends might help you take more informed decisions.
Merck & Co., Inc. dividend yield was 3.14% in 2024, and payout ratio reached 46.32%. The year before the numbers were 2.72% and 2.07 K% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Oct 4, 2025, the company has 75 K employees. See our rating of the largest employees — is Merck & Co., Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Merck & Co., Inc. EBITDA is 21.24 B CHF, and current EBITDA margin is 39.30%. See more stats in Merck & Co., Inc. financial statements.
Like other stocks, 6MK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Merck & Co., Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Merck & Co., Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Merck & Co., Inc. stock shows the sell signal. See more of Merck & Co., Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.